cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates

David N. Louis, David W. Ellison, Daniel J. Brat, Kenneth Aldape, David Capper, Cynthia Hawkins, Werner Paulus, Arie Perry, Guido Reifenberger, Dominique Figarella-Branger, Andreas von Deimling, Pieter Wesseling

Research output: Contribution to journalReview articleAcademicpeer-review


cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications. From 2016 to 2019 (Round 1), cIMPACT published four updates. Update 1 clarified the use of the term NOS (Not Otherwise Specified) and proposed use of the additional term NEC (Not Elsewhere Classified). Update 2 issued clarifications regarding two diagnoses: Diffuse Midline Glioma, H3 K27M-mutant and Diffuse Astrocytoma/Anaplastic Astrocytoma, IDH-mutant. Update 3 proposed molecular criteria that could be used in the setting of an IDH-wildtype diffuse or anaplastic astrocytic glioma without histological features of glioblastoma to infer that the tumor would behave similarly to a grade IV glioblastoma. Update 4 suggested that, in children and young adults, subtypes of IDH-wildtype/H3-wildtype diffuse gliomas may have distinct clinical features in the setting of a BRAFV600E mutation, FGFR1 alteration, other MAPK pathway alteration, or a MYB or MYBL1 rearrangement. The practical diagnostic relevance of these cIMPACT proposals is highlighted in this summary.
Original languageEnglish
Pages (from-to)469-472
Number of pages4
JournalBrain Pathology
Issue number4
Publication statusPublished - 1 Jul 2019

Cite this